{"id":56184,"date":"2023-04-25T13:06:33","date_gmt":"2023-04-25T11:06:33","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/"},"modified":"2023-04-25T13:06:33","modified_gmt":"2023-04-25T11:06:33","slug":"albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/","title":{"rendered":"Albatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation"},"content":{"rendered":"
\n

\nFunding is amplified by recognition as first Amgen Golden Ticket winner in Singapore<\/i><\/p>\n

<\/a><\/p>\n

SINGAPORE–(BUSINESS WIRE)–Albatroz Therapeutics<\/a>, a biotechnology company targeting tissue remodeling to stop cancer growth and treat arthritis, today announced it has secured $3 million USD in funding led by Outram Bio and SEEDS Capital to accelerate the development of therapeutic antibodies against a novel target that degrades the extracellular matrix, a key contributor to cancer and arthritis. The company also received the first Golden Ticket prize from Amgen<\/a> in Singapore, recognizing the viability of its science and business plan.<\/p>\n

\nCancer that has metastasized, spreading to other parts of the body, is notoriously difficult to treat and accounts for most cancer deaths. Albatroz has secured exclusive rights on a highly specific and novel target that blocks tumor growth and recurrence, including a range of therapeutic antibodies that inhibit this target.<\/p>\n

\n\u201cDegradation of the extracellular matrix is a critical component of both tumor growth and arthritis, however candidate drugs against this process have been limited in their use due to toxicity profiles,\u201d said Dr. Fred Bard, CEO and Scientific Co-Founder of Albatroz. \u201cWe are thrilled with the industry support that is allowing us to accelerate development of Albatroz\u2019s novel therapeutic antibodies in order to move toward the clinic. We look forward to collaborating with pharmaceutical and biotech innovators in order to maximize the impact of this science.\u201d<\/p>\n

\nWhile at the Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR) in Singapore, Dr. Bard published prominently on a pathway that controls protein glycosylation and drives extracellular matrix degradation. The study of the GalNAc-T Activation (GALA) glycosylation pathway led to the discovery of a new target, which becomes exposed at the cell surface after glycosylation. Activation of the target occurs specifically in tumors and arthritic synovial membranes, connective tissue that lines the joint capsule. Albatroz\u2019s targeted antibodies have high specificity for this target selectively reducing extracellular matrix degradation while minimizing toxicity.<\/p>\n

\n\u201cAlbatroz is building on careful, fundamental research comparing normal and cancer tissues, which led to the exciting discovery of a novel and broadly distributed target present on the surface of diverse solid tumors,\u201d said David Virshup, Director of the Programme in Cancer and Stem Cell Biology (CSCB) and Professor at Duke-NUS Medical School. \u201cThe therapeutic antibodies that Albatroz has developed may prevent the growth and metastasis of these cancers. These first-in-class agents have enormous potential to improve our ability to treat patients with cancer.\u201d<\/p>\n

\nA Recognized Leader in the Singapore Biotech Community<\/b><\/p>\n

\nAlbatroz also announced it is the first Amgen \u201cGolden Ticket\u201d recipient in Singapore.<\/a> A scientific committee at Amgen evaluated the strength and novelty of the scientific rationale, subject matter expertise of the leadership and business plan viability of the company and awarded Albatroz access to a fully-equipped, turnkey, and certified BSL-2 laboratory from NSG Biolabs.<\/p>\n

\n\u201cAmgen\u2019s sponsorship of the Golden Ticket award with NSG Biolabs captures what it means to support early-stage startups in their acceleration of bioscience innovation while contributing towards Singapore\u2019s growing biotech ecosystem. Having evaluated many strong entries from a diversity of startups, we are enthusiastic about the cancer therapy and anti-arthritic platform being developed by Albatroz Therapeutics and their continued progress in advancing novel therapies to improve the lives of patients with serious diseases. Congratulations to Albatroz Therapeutics,\u201d said Alan Russell, Ph.D., Vice President of Biologic Therapeutic Discovery at Amgen.<\/p>\n

\n\u201cAlbatroz Therapeutics is an exciting example of the burgeoning biotech industry in Singapore\u2013 Southeast Asia\u2019s largest biotech hub, and one that boasts cutting-edge research and attracts leading scientists from around the world,\u201d said Christopher Tan, Partner at Outram Bio, who has been appointed to Albatroz\u2019s Board of Directors. \u201cThe company has a comprehensive IP portfolio around the use of the target signaling pathway to discover and develop therapeutic antibodies, based on research that has been developed over the last decade, and fills a critical gap for patients suffering from arthritis and specific types of cancer that have been historically difficult to treat.\u201d<\/p>\n

\nAbout Albatroz Therapeutics<\/b><\/p>\n

\nAlbatroz Therapeutics is a Singapore-based biotechnology company developing first-in-class antibody therapeutics to treat solid tumors and arthritic disorders. The novel technology was developed by the founders\u2019 team at A*STAR\u2019s Institute of Molecular and Cellular Biology. Founded in 2020, the company holds an exclusive license for rights to the technology patent portfolio and is conducting further target validation, drug development, and preclinical studies. For more information, please visit www.albatroztherapeutics.com<\/a><\/p>\n

\nAbout Outram Bio<\/b><\/p>\n

\nOutram Bio backs adventurous scientists, engineers and entrepreneurs working to make an impact in patients\u2019 lives. Headquartered in Singapore, we invest in drugs, diagnostics and digital solutions developed by companies with a presence or interest in Asia. In addition to capital, we support startups with commercial talent, connect them with our international network of advisors, and help propel them into the global biotechnology ecosystem. The Outram Bio Fund is managed by Gordian Capital, a holder of a capital markets services license issued by the Monetary Authority of Singapore and Asia\u2019s leading institutional fund management platform. For more information, please visit www.outrambio.com<\/a> and www.gordian-capital.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Inquiries:<\/b>
Shira Derasmo
\n
Cuttlefish Communications
\n
+1 917-280-2497
\n
shira@cuttlefishpr.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Funding is amplified by recognition as first Amgen Golden Ticket winner in Singapore SINGAPORE–(BUSINESS WIRE)–Albatroz Therapeutics, a biotechnology company targeting tissue remodeling to stop cancer growth and treat arthritis, today announced it has secured $3 million USD in funding led by Outram Bio and SEEDS Capital to accelerate the development of therapeutic antibodies against a … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56184","6":"format-standard","7":"category-industry"},"yoast_head":"\nAlbatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Albatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Funding is amplified by recognition as first Amgen Golden Ticket winner in Singapore SINGAPORE–(BUSINESS WIRE)–Albatroz Therapeutics, a biotechnology company targeting tissue remodeling to stop cancer growth and treat arthritis, today announced it has secured $3 million USD in funding led by Outram Bio and SEEDS Capital to accelerate the development of therapeutic antibodies against a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-25T11:06:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230425005190\/en\/1772423\/21\/albatroz_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Albatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation\",\"datePublished\":\"2023-04-25T11:06:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\\\/\"},\"wordCount\":894,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425005190\\\/en\\\/1772423\\\/21\\\/albatroz_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\\\/\",\"name\":\"Albatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425005190\\\/en\\\/1772423\\\/21\\\/albatroz_logo.jpg\",\"datePublished\":\"2023-04-25T11:06:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425005190\\\/en\\\/1772423\\\/21\\\/albatroz_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425005190\\\/en\\\/1772423\\\/21\\\/albatroz_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Albatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Albatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/","og_locale":"en_US","og_type":"article","og_title":"Albatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation - Pharma Trend","og_description":"Funding is amplified by recognition as first Amgen Golden Ticket winner in Singapore SINGAPORE–(BUSINESS WIRE)–Albatroz Therapeutics, a biotechnology company targeting tissue remodeling to stop cancer growth and treat arthritis, today announced it has secured $3 million USD in funding led by Outram Bio and SEEDS Capital to accelerate the development of therapeutic antibodies against a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-25T11:06:33+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230425005190\/en\/1772423\/21\/albatroz_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Albatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation","datePublished":"2023-04-25T11:06:33+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/"},"wordCount":894,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230425005190\/en\/1772423\/21\/albatroz_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/","url":"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/","name":"Albatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230425005190\/en\/1772423\/21\/albatroz_logo.jpg","datePublished":"2023-04-25T11:06:33+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230425005190\/en\/1772423\/21\/albatroz_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230425005190\/en\/1772423\/21\/albatroz_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/albatroz-therapeutics-secures-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Albatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56184"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56184\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}